Samsung Bioepis Backed By EMA For First Lucentis Biosimilar
Byooviz Ranibizumab Biosimilar Recommended By EMA’s CHMP
Samsung Bioepis is set to make waves with the first ophthalmic biosimilar after the European regulator recommended that its ranibizumab biosimilar Byooviz receive a pan-European marketing authorization.
